<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: No formal guidelines exist to guide physicians caring for patients with <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> in their screening for management of patients with <z:e sem="disease" ids="C0392077" disease_type="Disease or Syndrome" abbrv="">cardiac sarcoidosis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a modified Delphi study to investigate if a consensus could be reached on the best approaches for screening for and management of <z:e sem="disease" ids="C0392077" disease_type="Disease or Syndrome" abbrv="">cardiac sarcoidosis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A modified Delphi study design with two rounds of questionnaires was used to investigate if a consensus existed among <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoid</z:e> experts in the United States on the best management approaches for <z:e sem="disease" ids="C0392077" disease_type="Disease or Syndrome" abbrv="">cardiac sarcoidosis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Experts were identified based on their national reputation as <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoid</z:e> experts and by being actively involved in <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> clinics at their institutions </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Overall agreement was low to moderate </plain></SENT>
<SENT sid="5" pm="."><plain>Agreement was reached on the role of history, physical examination, and 12-lead ECG in screening, echocardiogram, Holter monitor, myocardial fluorodeoxyglucose PET scan, and cardiac MRI in workup, and steroids in treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Agreement was not reached on the role of signal-averaged ECG in screening, optimum dose of <z:chebi fb="0" ids="8382">prednisone</z:chebi>, use of steroid-sparing agents, and duration of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Several comments underscore the diverse approaches and uncertainty that exist in managing <z:e sem="disease" ids="C0392077" disease_type="Disease or Syndrome" abbrv="">cardiac sarcoidosis</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our study highlights the dilemma that <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoid</z:e> experts face in their approach to <z:e sem="disease" ids="C0392077" disease_type="Disease or Syndrome" abbrv="">cardiac sarcoidosis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>It also highlights the lack of agreement among <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoid</z:e> experts on key aspects of diagnosis and management and stresses the importance of collaborative efforts to investigate the best strategies for screening for and management of <z:e sem="disease" ids="C0392077" disease_type="Disease or Syndrome" abbrv="">cardiac sarcoidosis</z:e> </plain></SENT>
</text></document>